Immunogenicity after CoronaVac vaccination

Basit Öğe Kaydı
dc.authorscopusid42661653300
dc.authorscopusid57218879837
dc.authorscopusid24483063300
dc.authorscopusid57363147500
dc.contributor.authorGüzel, Eda Çelik
dc.contributor.authorÇelikkol, Aliye
dc.contributor.authorErdal, Berna
dc.contributor.authorSedef, N.
dc.date.accessioned2022-05-11T14:02:44Z
dc.date.available2022-05-11T14:02:44Z
dc.date.issued2021
dc.departmentFakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Aile Hekimliği Ana Bilim Dalı
dc.departmentFakülteler, Tıp Fakültesi, Temel Tıp Bilimleri Bölümü, Tıbbi Biyokimya Ana Bilim Dalı
dc.departmentFakülteler, Tıp Fakültesi, Temel Tıp Bilimleri Bölümü, Tıbbi Mikrobiyoloji Ana Bilim Dalı
dc.description.abstractOBJECTIVE: This study aimed to investigate the seropositivity of CoronaVac-SinoVac vaccination in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) risk factors and comorbidities. METHODS: Immunoglobulin (IgG) antibody responses were examined on the 21st day after the second dose of CoronaVac-SinoVac 6 ?g vaccine on the 28th day. SARS-CoV-2 IgG antibody levels were measured by using the enzyme-linked immunosorbent assay method in vaccinated health care workers (n=134) (Group I), vaccinated polymerase chain reaction (PCR) (+) who had coronavirus-19 (COVID-19) disease (n=21) (Group II), and unvaccinated PCR (+) (n=28) (Group III) participants. Subgroups were formed in Group I according to the presence of COVID-19 risk factors and comorbidities (diabetes mellitus, cardiovascular disease, and asthma/allergy) and demographic data. RESULTS: Seropositivity rates were 95.5, 100, and 89.3% for Groups I, II, and III, respectively. IgG antibody levels were found significantly higher in the group between the ages of 20–30 in group I compared to those aged 31–50 and over 50 (both p<0.01). It was found significantly higher in normal-weight individuals than in the overweight and obese group (both p<0.01). IgG antibody levels were found significantly lower in people with cardiovascular disease and diabetes mellitus compared with those who did not (p<0.05 and p<0.001, respectively). There was a negative correlation between IgG antibody response values and body mass index and age in Group I (r= -0.336, p<0.001 and r= -0.307, p<0.001, respectively). CONCLUSION: IgG antibody values decrease with age and with increasing body mass index. The presence of comorbidities (i.e., diabetes mellitus and cardiovascular disease) decreased COVID-19 IgG antibody values. © 2021 Associacao Medica Brasileira. All rights reserved.
dc.identifier.doi10.1590/1806-9282.20210389
dc.identifier.endpage1408
dc.identifier.issn0104-4230
dc.identifier.issue10en_US
dc.identifier.pmid35018966
dc.identifier.scopus2-s2.0-85120649825
dc.identifier.scopusqualityQ3
dc.identifier.startpage1403
dc.identifier.urihttps://doi.org/10.1590/1806-9282.20210389
dc.identifier.urihttps://hdl.handle.net/20.500.11776/4460
dc.identifier.volume67
dc.identifier.wosWOS:000726787100006
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorGüzel, Eda Çelik
dc.institutionauthorÇelikkol, Aliye
dc.institutionauthorErdal, Berna
dc.institutionauthorSedef, N.
dc.language.isoen
dc.publisherAssociacao Medica Brasileira
dc.relation.ispartofRevista da Associacao Medica Brasileira
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectComorbidity
dc.subjectCOVID-19 virus disease
dc.subjectImmunogenicity
dc.subjectRisk factors
dc.subjectVaccine
dc.subjectcoronavac
dc.subjectimmunoglobulin G antibody
dc.subjectvirus antibody
dc.subjectadult
dc.subjectage
dc.subjectantibody blood level
dc.subjectantibody response
dc.subjectArticle
dc.subjectasthma
dc.subjectbody mass
dc.subjectcardiovascular disease
dc.subjectcomorbidity
dc.subjectcomparative effectiveness
dc.subjectcontrolled study
dc.subjectcoronavirus disease 2019
dc.subjectdemography
dc.subjectdiabetes mellitus
dc.subjectenzyme linked immunosorbent assay
dc.subjectfemale
dc.subjecthealth care personnel
dc.subjecthuman
dc.subjectmajor clinical study
dc.subjectmale
dc.subjectoutcome assessment
dc.subjectpolymerase chain reaction
dc.subjectprospective study
dc.subjectrisk factor
dc.subjectSevere acute respiratory syndrome coronavirus 2
dc.subjecttreatment outcome
dc.subjectvaccination
dc.subjectvaccine immunogenicity
dc.subjectyoung adult
dc.subjectAdult
dc.subjectAntibodies, Viral
dc.subjectCOVID-19
dc.subjectCOVID-19 Vaccines
dc.subjectHumans
dc.subjectSARS-CoV-2
dc.subjectVaccination
dc.subjectYoung Adult
dc.titleImmunogenicity after CoronaVac vaccination
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
4460.pdf
Boyut:
775.94 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
Tıp Fakültesi Koleksiyonu